ENG/中
美国
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerGPT
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
港股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
生物医药B类股
430.463
+8.716
2.07%
手动刷新
涨家数:
27
跌家数:
4
平家数:
3
市盈率:
- -
高:
431.911
开:
421.747
低:
421.747
收:
421.747
数据加载中...
总览
新闻资讯
创新药企业真实生物港股IPO:2024年研发投入减少36.6%,两年亏损8亿元
蓝鲸财经
·
1小时前
郑栅洁:越来越多的产品装上了“中国芯” 打压封锁只会让中国加快步伐
金十财经
·
1小时前
拓新药业:子公司奥拉帕利原料药上市申请获批
美港电讯
·
2小时前
【拓新药业:全资子公司奥拉帕利原料药获得上市申请批准通知书】拓新药业(301089.SZ)公告称,公司全资子公司新乡制药股份有限公司的奥拉帕利原料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》,并批准注册。奥拉帕利主要用于治疗携带胚系或体系BRCA突变的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌。此次批准将丰富公司产品线,提升市场竞争力,对国内市场产生积极影响。但需注意医药产品销售受市场、政策、环境变化等不确定因素影响,存在销售不达预期的风险。
金融界
·
2小时前
天康生物:目前并无将主营业务转接至天康制药的计划
美港电讯
·
2小时前
东曜药业-B盘中异动 下午盘股价大涨9.89%报2.000港元
市场透视
·
2小时前
港股异动 | 科济药业-B(02171)涨近7% Claudin18.2 CAR-T纳入突破性治疗药物品种 有望上半年申请上市
智通财经
·
2小时前
康宁杰瑞制药-B盘中异动 下午盘股价大跌5.29%
市场透视
·
3小时前
沛嘉医疗-B(09996)股价显著上升12.23%,现价港币$4.68
阿斯达克财经
·
3小时前
同源康医药-B盘中异动 下午盘股价大跌6.45%报29.000港元
市场透视
·
3小时前
欧康维视生物-B盘中异动 股价大涨5.15%报4.900港元
市场透视
·
3小时前
创新药概念震荡拉升 热景生物涨超15%创2年多新高
南方财经网
·
4小时前
【欧普康视等成立眼视光科技公司 含诊所服务业务】 公开资料显示,近日,郑州欧普康视眼视光科技有限公司成立,法定代表人为闫霞,注册资本100万元,经营范围包含:第一类医疗器械销售;诊所服务;电子产品销售;文具用品零售;体育用品及器材零售;医院管理;企业管理;品牌管理等。股权数据显示,该公司由河南一眸科技有限公司、欧普康视旗下欧普康视投资有限公司共同持股。
金融界
·
4小时前
心通医疗-B(02160)上涨20.79%,报1.22元/股
金融界
·
4小时前
华领医药-B(02552)股价下跌5.328%,现价港币$2.31
阿斯达克财经
·
4小时前
医药外包概念股集体走强 维亚生物涨6.77% 机构指AI技术渗透加速CXO产业范式革新
金吾资讯
·
4小时前
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":430.4633,"timestamp":1741248510375,"preClose":421.74713,"halted":0,"volume":196751826,"delay":0,"changeRate":0.020667,"change":8.716156,"pbRate":3.352817,"amount":2078205803,"amplitude":0.024099,"prevYearClose":331.1933,"fiveDayClose":431.446,"twentyDayClose":333.662,"turnoverRate":0.00762,"marketCap":241153069920,"floatMarketCap":226975358368,"peRate":-16.712341},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":431.91098,"amplitude":0.024099,"preClose":421.74713,"low":421.74713,"pbRate":"3.352817","latestPrice":430.4633,"volume":196751826,"delay":0,"open":421.74713,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":431.446,"twentyDayClose":333.662,"sixtyDayClose":346.493,"secType":"PLATE","market":"HK","turnoverRate":0.00762,"peRate":-16.712341,"marketCap":241153069920,"floatMarketCap":226975358368,"timestamp":1741248510375,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":27,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517781138","title":"创新药企业真实生物港股IPO:2024年研发投入减少36.6%,两年亏损8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517781138","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517781138?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 16:19","pubTimestamp":1741249195,"startTime":"0","endTime":"0","summary":"近日,河南药企真实生物再次向港交所申请主板上市,中金公司为其独家保荐人。作为创新药公司,真实生物目前只有阿兹夫定一款药品实现商业化,其他药品多处于早期研发阶段。阿兹夫定作为新冠口服药,一度让真实生物成为市场中的“明星”。但随着疫情平息,真实生物收入出现下滑,研发投入也在缩减。2022年7月,阿兹夫定获得附条件批准上市,成为首款国产新冠口服抗病毒药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252390","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["HSTECH","YANG","BK1574","BK1161","HSCEI","06978"],"gpt_icon":1},{"id":"2517180650","title":"郑栅洁:越来越多的产品装上了“中国芯” 打压封锁只会让中国加快步伐","url":"https://stock-news.laohu8.com/highlight/detail?id=2517180650","media":"金十财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517180650?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 16:17","pubTimestamp":1741249023,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://flash-api.jin10.com/get_flash_list?channel=2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_jinshicaijing","symbols":["BK1574","159992","BK1161","161631","06978"],"gpt_icon":0},{"id":"2517827531","title":"拓新药业:子公司奥拉帕利原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2517827531","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517827531?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:56","pubTimestamp":1741247773,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1191","301089","01477","BK0239","BK1574"],"gpt_icon":0},{"id":"2517182501","title":"【拓新药业:全资子公司奥拉帕利原料药获得上市申请批准通知书】拓新药业(301089.SZ)公告称,公司全资子公司新乡制药股份有限公司的奥拉帕利原料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》,并批准注册。奥拉帕利主要用于治疗携带胚系或体系BRCA突变的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌。此次批准将丰富公司产品线,提升市场竞争力,对国内市场产生积极影响。但需注意医药产品销售受市场、政策、环境变化等不确定因素影响,存在销售不达预期的风险。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517182501","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517182501?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:45","pubTimestamp":1741247149,"startTime":"0","endTime":"0","summary":"拓新药业(301089.SZ)公告称,公司全资子公司新乡制药股份有限公司的奥拉帕利原料药收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》,并批准注册。奥拉帕利主要用于治疗携带胚系或体系BRCA突变的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌。此次批准将丰富公司产品线,提升市场竞争力,对国内市场产生积极影响。但需注意医药产品销售受市场、政策、环境变化等不确定因素影响,存在销售不达预期的风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06154548559054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301089","01477","09939","BK1515","BK1161","BK0239","BK1574","159938","BK1191"],"gpt_icon":0},{"id":"2517848601","title":"天康生物:目前并无将主营业务转接至天康制药的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2517848601","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517848601?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:37","pubTimestamp":1741246653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1191","BK0027","BK0201","002100","BK0188","BK1574","01477","000061","BK0046","BK0210","BK0028","BK0238","BK0016","BK0195","BK0168"],"gpt_icon":0},{"id":"2517846401","title":"东曜药业-B盘中异动 下午盘股价大涨9.89%报2.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517846401","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517846401?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:27","pubTimestamp":1741246036,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘15时27分,东曜药业-B股票出现波动,股价大幅拉升9.89%。截至发稿,该股报2.000港元/股,成交量50.88万股,换手率0.07%,振幅10.99%。资金方面,该股资金流入73.5648万港元,流出22.0408万港元。东曜药业-B股票所在的生物技术行业中,整体涨幅为0.55%。股价大跌之后,今日上午,乐普生物随即发布公告回应新药上市不顺利的原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306152717abeaeb8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306152717abeaeb8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01875","BK1161"],"gpt_icon":0},{"id":"2517189469","title":"港股异动 | 科济药业-B(02171)涨近7% Claudin18.2 CAR-T纳入突破性治疗药物品种 有望上半年申请上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2517189469","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517189469?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 15:14","pubTimestamp":1741245299,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科济药业-B涨近7%,截至发稿,涨4.74%,报15.92港元,成交额1.01亿港元。消息面上,科济药业近日宣布,公司自主研发的舒瑞基奥仑赛注射液已被国家药品监督管理局药品审评中心纳入突破性治疗药物品种名单,拟定适应症为既往接受过至少二线治疗失败的Claudin18.2表达阳性的晚期胃/食管胃结合部腺癌。公司预计将于2025年上半年向国家药品监督管理局递交舒瑞基奥仑赛注射液的新药上市申请。此次增资完成后,公司的权益将由100%稀释至92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4230","BK4022","BK1585","02171","BK1574","BK1587","CAR"],"gpt_icon":0},{"id":"2517186283","title":"康宁杰瑞制药-B盘中异动 下午盘股价大跌5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517186283","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517186283?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:58","pubTimestamp":1741244288,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时58分,康宁杰瑞制药-B股票出现波动,股价快速下挫5.29%。康宁杰瑞制药-B股票所在的生物技术行业中,整体涨幅为0.47%。消息层面,截至14时58分,《康宁杰瑞制药绩后大涨!首次实现年度盈利》资讯为影响康宁杰瑞制药-B的重要信息。康宁杰瑞制药绩后大涨超10%,领涨恒生医药ETF持仓股,再鼎医药、巨子生物、诺诚健华等涨幅靠前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306145809a261f929&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306145809a261f929&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2517868251","title":"沛嘉医疗-B(09996)股价显著上升12.23%,现价港币$4.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2517868251","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517868251?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:40","pubTimestamp":1741243200,"startTime":"0","endTime":"0","summary":"[上升股]沛嘉医疗-B(09996) 股价在下午02:40比前收市价显著上升12.23%,现股价为港币$4.68。至目前为止,今日最高价为$4.68,而最低价为$4.21。总成交量为347.3万股,总成交金额为港币$1.573千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2503068824/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","159891","BK1100","09996","BK1583"],"gpt_icon":0},{"id":"2517186478","title":"同源康医药-B盘中异动 下午盘股价大跌6.45%报29.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517186478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517186478?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:23","pubTimestamp":1741242194,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时23分,同源康医药-B股票出现波动,股价急速跳水6.45%。截至发稿,该股报29.000港元/股,成交量39.85万股,换手率0.11%,振幅9.52%。资金方面,该股资金流入665.168万港元,流出549.195万港元。同源康医药-B股票所在的生物技术行业中,整体涨幅为0.51%。同源康医药-B公司简介:浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306142314abeada0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306142314abeada0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02410","BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2517183534","title":"欧康维视生物-B盘中异动 股价大涨5.15%报4.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517183534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517183534?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 14:13","pubTimestamp":1741241592,"startTime":"0","endTime":"0","summary":"2025年03月06日下午盘14时13分,欧康维视生物-B股票出现波动,股价快速上涨5.15%。截至发稿,该股报4.900港元/股,成交量183.45万股,换手率0.22%,振幅5.15%。资金方面,该股资金流入534.561万港元,流出211.619万港元。欧康维视生物-B股票所在的生物技术行业中,整体涨幅为0.48%。欧康维视生物-B公司简介:欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306141312a261ef0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306141312a261ef0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2517883931","title":"创新药概念震荡拉升 热景生物涨超15%创2年多新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2517883931","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517883931?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:56","pubTimestamp":1741240575,"startTime":"0","endTime":"0","summary":"南方财经3月6日电,创新药概念震荡拉升,午后热景生物拉升涨超15%,股价创2年多新高,博瑞医药涨近10%,诺思格、一品红、荣昌生物、艾力斯、药明康德等涨幅靠前。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338418745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2517334188","title":"【欧普康视等成立眼视光科技公司 含诊所服务业务】 公开资料显示,近日,郑州欧普康视眼视光科技有限公司成立,法定代表人为闫霞,注册资本100万元,经营范围包含:第一类医疗器械销售;诊所服务;电子产品销售;文具用品零售;体育用品及器材零售;医院管理;企业管理;品牌管理等。股权数据显示,该公司由河南一眸科技有限公司、欧普康视旗下欧普康视投资有限公司共同持股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517334188","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517334188?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:55","pubTimestamp":1741240523,"startTime":"0","endTime":"0","summary":"公开资料显示,近日,郑州欧普康视眼视光科技有限公司成立,法定代表人为闫霞,注册资本100万元,经营范围包含:第一类医疗器械销售;诊所服务;电子产品销售;文具用品零售;体育用品及器材零售;医院管理;企业管理;品牌管理等。股权数据显示,该公司由河南一眸科技有限公司、欧普康视旗下欧普康视投资有限公司共同持股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06135548557348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09996","BK1583","BK0251","159883","09997","BK1222","300595","BK1574","BK1100"],"gpt_icon":0},{"id":"2517188327","title":"心通医疗-B(02160)上涨20.79%,报1.22元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517188327","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517188327?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:51","pubTimestamp":1741240306,"startTime":"0","endTime":"0","summary":"3月6日,心通医疗-B盘中上涨20.79%,截至13:51,报1.22元/股,成交2516.96万元。心通医疗是一家中国领先的医疗器械企业,主要从事结构性心脏病领域的经导管和手术解决方案的研发和商业化,产品包括VitaFlow系列经导管主动脉瓣植入产品、经导管二尖瓣治疗产品、经导管三尖瓣治疗产品、外科瓣膜产品和手术配件等。截至2024年中报,心通医疗-B营业总收入2.23亿元、净利润-5646.1万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06135148557357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","02160","BK1583","BK1100"],"gpt_icon":0},{"id":"2517188442","title":"华领医药-B(02552)股价下跌5.328%,现价港币$2.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2517188442","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517188442?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:50","pubTimestamp":1741240200,"startTime":"0","endTime":"0","summary":"[下跌股]华领医药-B(02552) 股价在下午01:50比前收市价下跌5.328%,现股价为港币$2.31。至目前为止,今日最高价为$2.59,而最低价为$2.31。总成交量为756.05万股,总成交金额为港币$1.857千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2503062736/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1191","02552"],"gpt_icon":0},{"id":"2517512188","title":"医药外包概念股集体走强 维亚生物涨6.77% 机构指AI技术渗透加速CXO产业范式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2517512188","media":"金吾资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517512188?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 13:48","pubTimestamp":1741240123,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股集体走强,截至发稿,维亚生物 涨6.77%,康龙化成涨3.92%,泰格医药和药明康德涨3.24%,药明生物涨2.38%消息面上,国泰君安发布研报称,AI技术渗透加速CXO产业范式革新。AI技术在生物医药领域深度应用有望重构CXO产业价值链。全球药企降本增效诉求升级,叠加AI技术成熟度提升,驱动CXO企业加速智能化转型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306134913963bb5f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306134913963bb5f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1515","BK1161","03347","09939","BK1574","02359","01873","BK1141","03759"],"gpt_icon":0}],"pageSize":16,"totalPage":42,"pageCount":1,"totalSize":659}]}}